Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Ann Med ; 48(3): 149-61, 2016.
Article in English | MEDLINE | ID: mdl-26911282

ABSTRACT

Human Papilloma Virus (HPV) is one of the most common sexually transmitted pathogen, globally. Oncogenic types of HPV are the causative agents of many neoplastic diseases, including cervical cancer, which ranks as the most common cancer affecting females in developing countries. HPV infection of the cervical epithelium and the subsequent integration of viral DNA into the host genome are the major risk factors for cervical cancer. The scientific discovery of HPV as the causal agent of cervical cancer has led to the development of HPV-based diagnostic tools. Prophylactic vaccines, based on the oncogenic HPV type virus-like particles have been introduced in several developed countries as a preliminary preventive approach. Nevertheless, it remains a continuous threat to women in developing countries, where the prophylactic vaccines are unaffordable and organized screening programmes are lacking. This warrants implementation of prevention strategies that will reduce cervical cancer-related mortality. In this review, we have discussed molecular pathogenesis of HPV infection and the risk factors associated with it. The diagnosis, treatment and prevention strategies of HPV-related cervical cancer have also been discussed.


Subject(s)
Oncogene Proteins, Viral/metabolism , Papillomaviridae/metabolism , Papillomavirus Infections , Sexually Transmitted Diseases/therapy , Uterine Cervical Neoplasms/therapy , DNA, Viral/isolation & purification , DNA, Viral/metabolism , Developing Countries , Disease Eradication/methods , Early Detection of Cancer/methods , Female , Humans , Mass Screening/methods , Papillomaviridae/genetics , Papillomaviridae/immunology , Papillomavirus Infections/complications , Papillomavirus Infections/diagnosis , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/therapeutic use , Prevalence , Risk Factors , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/prevention & control , Sexually Transmitted Diseases/virology , Uterine Cervical Neoplasms/diagnosis , Uterine Cervical Neoplasms/prevention & control , Uterine Cervical Neoplasms/virology
2.
Int J Biochem Cell Biol ; 43(3): 331-41, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20883815

ABSTRACT

Paclitaxel is the most promising chemotherapeutic agent of plant origin despite its high cost and dose-limiting toxicity. Our earlier report has shown that cervical cancer cells can be sensitized by curcumin to paclitaxel-induced apoptosis through down-regulation of NF-κB and Akt. In the present study we have attempted to decipher the signaling pathways regulating the synergism of paclitaxel and curcumin. The study has clearly proved that Akt and NF-κB function successively in the sequence of paclitaxel induced signaling events where Akt is upstream of NF-κB. While inhibition of NF-κB led to complete inhibition of the synergism of paclitaxel and curcumin, inhibition of Akt brought about only partial reduction of the same, suggesting that, apart from Akt, there are other pathways induced by paclitaxel leading to NF-κB activation, which are also down-regulated by curcumin. Inactivation of NF-κB did not affect the activation of Akt and survivin, while that of Akt significantly inhibited NF-κB and completely inhibited up-regulation of survivin. Up-regulation of Cyclin-D1, Cox-2, XIAP and cIAP1 and phosphorylation of MAPKs, were completely inhibited on inactivation of NF-κB assigning a key regulatory role to NF-κB in the synergistic effect of paclitaxel and curcumin. While up-regulation of survivin by paclitaxel is regulated by Akt, independent of NF-κB, inactivation of neither Akt nor NF-κB produced any change in Bcl-2 level suggesting a distinct pathway for its action. As curcumin could effectively down-regulate all these survival signals induced by paclitaxel, we suggest it as a potent chemosensitizer to improve the therapeutic index of paclitaxel.


Subject(s)
Curcumin/pharmacology , Down-Regulation/drug effects , Mitogen-Activated Protein Kinases/metabolism , NF-kappa B/metabolism , Paclitaxel/pharmacology , Proto-Oncogene Proteins c-akt/metabolism , Signal Transduction/drug effects , Cell Cycle/drug effects , Cell Survival/drug effects , Cyclin D1/genetics , Cyclin D1/metabolism , Cyclooxygenase 2/genetics , Cyclooxygenase 2/metabolism , Drug Synergism , Enzyme Activation/drug effects , Gene Expression Regulation, Neoplastic/drug effects , HeLa Cells , Humans , Inhibitor of Apoptosis Proteins/metabolism , Models, Biological , Proto-Oncogene Proteins c-bcl-2/metabolism , Survivin , Transcription Factor AP-1/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL